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Why the increased incidence of
melanoma in young CMN patients?
An example of a postnatally acquired
Q61K mutation in the second copy of
the NRAS gene (or loss of the normal
allele) in a CMN cell has been corre-
lated to the onset of malignant mela-
noma in one patient; similar loss of
heterozygosity of NRAS Q61R was
linked to nevomelanocyte proliferation
within the CNS, causing NCM in another
(Kinsler et al., 2013). However, hetero-
zygous Q61R and Q61K NRAS muta-
tions have been observed in primary CNS
melanomas developing in two children
with CMN, where the same heterozygous
NRAS mutation had also been identified
in the CMN itself (Pedersen et al., 2013).
Curiously, no reliable case of melanoma
arising within an associated small CMN
has yet been reported, although these
‘‘satellite’’ lesions bear the same NRAS
mutations as the primary, large CMN,
and they are often exposed to sunlight
(Charbel et al., 2014; Kinsler et al., 2013).
Also, intriguingly, there are no reports of
any coincident BRAF and NRAS muta-
tions in the same CMN, despite the highly
sensitive detection techniques that have
been used.
Unlike blue nevi, the most superficial
component of a CMN is the most highly
pigmented, conferring brown-to-black
shades to the overlying epidermis. During
childhood, while the skin continues to
mature postnatally, CMN can evolve in
hue or surface texture. CMN may also
have congenitally fewer sweat glands
than unaffected skin, resulting in poten-
tial overheating episodes or increased
sweating in other areas of the body to
compensate. Areas of larger CMN may
have notably less fat under the skin,
particularly around the flanks, limbs and
buttocks. The CMN-involved epidermis
may be dry or prone to atopic dermatitis
in correlation with disorganized or absent
sebaceous glands. Intermittent or chronic
severe pruritis and mast cell infiltration of
large CMN have also been reported at a
recent conference (http://cmnexperts.org).
It remains unclear whether the somatic
mutations identified in human CMN are
restricted to melanoblasts or may also
extend to other neural crest or even
neuroepithelial derivatives, but the latter
scenario appears likely. Interestingly, tar-
geting of Braf V600E to specific sensory
neurons of the mouse dorsal root ganglia,
whose axons harbor unpigmented mela-
noblasts and which are also derived from
neural crest cells, changes their fate,
leading to overexpression of protein med-
iators of chronic itch and to intractable
scratching behavior (Zhao et al., 2013). If
the somatic mutations found in CMN are
also present in or around the cells of
peripheral nerves, using sensitive detec-
tion technologies such as those employed
by Charbel et al. (2014) and others will
have important and perhaps unexpected
implications for management.
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A Fibronectin-Derived Cell Survival
Peptide Belongs to a New Class of
Epiviosamines
Tomoo Ohashi1
In this issue, Lin et al. report the discovery of P12, a 14 amino acid peptide from
the first fibronectin (FN) type III domain of FN, which has the capability of
enhancing cell survival in culture and improving wound healing in rat skin. P12
belongs to a new class of bioactive peptides that they have named epiviosamines.
Epiviosamines may have clinical applications.
Journal of Investigative Dermatology (2014) 134, 882–884; doi:10.1038/jid.2013.470
Fibronectin (FN) is an extracellular
matrix (ECM) protein. It can bind a
variety of integrins on the cell surface
as well as many other molecules such as
gelatin (denatured collagen), fibrin (fibri-
nogen), heparin/heparan sulfate, tissue
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transglutaminase, tenascin, fibulin, and
fibrillin. FN molecules also associate
with each other to form matrix fibrils,
which are crucial for development
(Schwarzbauer and DeSimone, 2011).
Thus, FN molecules have the ability to
work as a scaffold for cells by interac-
ting with other extracellular molecules,
including themselves, for biological
functions. An increasing number of
studies has indicated recently that FN
interacts with growth factors (see especi-
ally the review article by Hynes (2009)).
Although insulin-like growth factors
seem to interact with FN indirectly
through insulin-like growth factor bind-
ing proteins, many other growth factors
appear to bind FN directly. Several
studies have mapped the growth factor
binding sites on FN. Vascular endo-
thelial cell growth factor (VEGF)
interacts with FN type III domains 12–
14 (FNIII12–14; Wijelath et al., 2006),
which comprise the second heparin bin-
ding site (Hep-II), and VEGF-induced
endothelial cell migration and proli-
feration were enhanced in the pre-
sence of FNIII12–14. Martino and
Hubbell (2010) found that FNIII12–14
was the locus of interaction for growth
factors from many families, including
VEGF, platelet-derived growth factor
(PDGF), fibroblast growth factor, trans-
forming growth factor-b, and members
of the neurotrophin families. Growth
factor-induced cell proliferation was
increased in the presence of FNIII12–
14, although FNIII12–14 had no effect
on growth factor-induced migration.
In contrast to the studies of Martino
and Hubbell (2010), who broadly
screened FNIII12–14 binding to growth
factors, Lin et al. (2011) focused on the
interaction between FN and PDGF-BB
(the homodimeric BB isoform), which
is a potent fibroblast survival factor.
They found that PDGF-BB could bind
FNIII1, FNIII13–14, and the variable (V)
domain (also called connecting seg-
ment), and that PDGF-BB-enhanced
fibroblast survival was increased in the
presence of FN fragments containing
these domains. Following up their pre-
vious study, Lin et al. (2014) in this
issue report that PDGF-BB can bind a 14
amino acid peptide derived from FNIII1,
called P12, which shows enhanced cell
survival activity.
In the 1980s, before the integrins
were discovered, many researchers
found that FN had cell adhesion activ-
ity, and they attempted to map the cell
binding site by dissecting the FN mole-
cule with proteases and chemicals.
Ruoslahti and his colleagues narrowed
the binding site location down to a 108
amino acid region. Remarkably, the
story did not end there. With the use
of synthetic peptides they discovered
that the RGDS peptide was sufficient
for cell binding. The fourth residue,
serine, appeared to be variable, thus
RGD was identified as the minimal
binding sequence (see the essay by
Ruoslahti (2003) for a historical
perspective). (The RGD peptide is
now recognized as being the shortest
peptide that has biological activity.) It
was then shown that engineered
circular RGD peptides (cyclic RGD)
have even stronger activities than
linear peptides, probably because
they mimic a naturally occurring loop
structure. This discovery led to the
development of many RGD-based
drugs that target integrins. Later,
Ruoslahti’s group found an FN
peptide that was able to induce FN
aggregation. As this peptide was
derived from the C terminus of FNIII1,
it was originally called III1-C, but it
was renamed anastellin after dis-
covery of its anti-angiogenic activity
(Yi and Ruoslahti, 2001). Most
recently, Gee et al. (2013) reported
that the SLLISWD peptide from strand
B of FNIII10 was also able to induce
FN aggregation. They postulated that
this peptide could exchange with
b-strands in other FNIII domains,
causing sequential domain swapping
and the formation of FN aggregates.
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Figure 1. Structural model of P12. (a) The parent domain, FNIII1, consists of a b-sandwich structure
with A, B, and E strands on one side and C, C0, F, and G strands on the other. The region corresponding to P12
is shown in green. (b) A surface-model shows that the majority of the P12 residues are exposed on the surface
(labeled in black). Ile-4 and Ser-5 are hidden on the back. (c) The structure of P12 extracted from III1 is shown
with a space-filling model. Surface-exposed residues are labeled in black; other residues are in gray.
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Lin et al. (2014) used similar tactics to
find the shortest peptide required for
fibroblast survival and PDGF-BB bind-
ing. By shortening a peptide derived
from FNIII1 until activity was lost, they
were able to identify P12, a 14 amino
acid peptide (PSHISKYILRWRPK) that
could not be truncated any further.
A striking feature of P12 is that it can
recapitulate the activity of the parent
domain (FNIII1) just as in the case of
the RGD peptide. This is in contrast to
the other FN-derived peptides, anastel-
lin and SLLISWD, whose activities are
unique to themselves, so that their
active sites are thought to be cryptic
in the parent proteins. This makes me
wonder where P12 is located in FNIII1.
The tertiary structure of FNIII1 shows a
typical FNIII b-sandwich structure
(Gao et al., 2003), with three strands
(A, B, and E) on one side and four
strands (C, C0, F, and G) on the other
(Figure 1a). P12 is made up of the
complete C strand, as well as several
loop residues, mostly from the B–C
loop (Figure 1a, in green). Because
FNIII1 is a relatively stable FNIII
domain in solution (Ohashi and
Erickson, 2011), it is likely that the
structure of P12 within FNIII1 reflects
the structure of P12 alone. The surface-
exposed residues, labeled in Figure 1b
and c, include several positively charged
amino acids, suggesting an electrostatic
interaction with PDGF-BB. However the
N-terminal proline, which is required for
activity, suggests that peptide conforma-
tion may have a role as well. This is
purely speculative, however, until a
structure can be obtained of P12 alone
or as a P12/PDGF-BB complex.
P12 belongs to a new
class of bioactive peptides
named epiviosamines.
Interactions between ECM proteins
and growth factors were only thought
to concentrate growth factors and to
enhance their multimerization for sig-
naling. However, recent studies indi-
cate that binding of growth factors to
ECM proteins may enhance interac-
tions between multi-domain ECM pro-
teins, such as FN, with cell surface
receptors, mostly integrins (Hynes,
2009). Thus, complexes of ECM
proteins and growth factors appear to
co-regulate signaling through both
integrin and growth factor receptors.
Surprisingly, the discovery of P12
reveals that a small peptide can
mimic the role of FN with PDGF-BB,
suggesting that some ECM–growth fac-
tor interactions may be less complex.
P12 can not only bind to PDGF-BB, but
also promote cell survival and improve
rat skin burns in a dose-dependent man-
ner. This growth factor-induced cell
survival activity led Lin et al. (2011) to
propose that P12 belongs to a new class
of bioactive peptides that they call
epiviosamines, a name that combines
the Greek word, epivios, which means
‘‘to survive in the face of adversity’’,
with amine for peptide. P12 and other
yet to be discovered epiviosamines may
have clinical potential, especially in the
reduction of cell death after tissue
damage.
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